Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06880549 | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | recruiting | Phase 1 | 42 | ModernaTX, Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07728942 | SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 70 | Solve TherapeuticsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol |
| active not recruiting |
| Phase 1 |
| 350 |
| NRG OncologyOTHER |
| 2 |
| Aug 7, 2026 |
| clinicaltrials |
| NCT05502393 | A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 133 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05608148 | Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors | recruiting | Phase 1 | 61 | Kyushu UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05853367 | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | active not recruiting | Phase 1 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Aug 7, 2026 | clinicaltrials |
| NCT07038369 | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | active not recruiting | Phase 1 | 134 | Atavistik Bio, IncINDUSTRY | 4 | Aug 7, 2026 | clinicaltrials |
| NCT07753590 | A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 258 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT00777582 | Phase I Comparative Bioavailability Study | active not recruiting | Phase 1 | 197 | AstraZenecaINDUSTRY | 4 | Aug 6, 2026 | clinicaltrials |
| NCT05944224 | A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 63 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 499 | Arvinas Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07751042 | Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | recruiting | Phase 1 / Phase 2 | 220 | Strand Therapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06160752 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations(SURF201) | active not recruiting | Phase 1 | 40 | Tyra Biosciences, IncINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | recruiting | Phase 1 / Phase 2 | 36 | Vector Vitale LLCINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06816108 | A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors | active not recruiting | Phase 1 | 35 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07256756 | A Study of GC203 TIL in Advanced Solid Tumors (NF) | recruiting | Phase 1 | 8 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07294872 | A Study of TIL in Advanced Solid Tumors (CZ) | not yet recruiting | Phase 1 | 30 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05238792 | Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors(ATTACK) | recruiting | Phase 1 | 24 | Children's National Research InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06380660 | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 298 | Acerand Therapeutics (Shanghai) LimitedINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06832982 | Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 | recruiting | Phase 1 | 66 | Shanghai Pushi Medical Science Co. LtdINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07744763 | A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT01434316 | Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 121 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05687110 | Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes | recruiting | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 2 | Aug 3, 2026 | clinicaltrials |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 370 | Revolution Medicines, Inc.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07601243 | Study of GS-2426 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 174 | Gilead SciencesINDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02535312 | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03030378 | Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors | active not recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04616534 | Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors | active not recruiting | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05372640 | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05691491 | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | recruiting | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739966 | A Study of DS-3939a in Participants With Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 400 | Daiichi SankyoINDUSTRY | 0 | Jul 31, 2026 | clinicaltrials |
| NCT03168737 | 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients | active not recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04337177 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | active not recruiting | Phase 1 | 20 | Valent Technologies, LLCINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05039632 | Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | active not recruiting | Phase 1 / Phase 2 | 184 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT07374419 | Atamparib in Patients With Advanced Solid Tumors(PARP7) | recruiting | Phase 1 / Phase 2 | 178 | Nerviano Medical Sciences (Shanghai) Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07524140 | A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Eilean TherapeuticsINDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT04058756 | Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments | active not recruiting | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 17 | Jul 28, 2026 | clinicaltrials |
| NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | recruiting | Phase 1 | 92 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05907980 | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | recruiting | Phase 1 | 209 | Chugai PharmaceuticalINDUSTRY | 2 | Jul 28, 2026 | clinicaltrials |
| NCT06031441 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 65 | Genentech, Inc.INDUSTRY | 5 | Jul 28, 2026 | clinicaltrials |
| NCT07042100 | A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 177 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 3 | Jul 28, 2026 | clinicaltrials |
| NCT05840224 | Study of GS-4528 in Adults With Solid Tumors | active not recruiting | Phase 1 | 182 | Gilead SciencesINDUSTRY | 6 | Jul 27, 2026 | clinicaltrials |
| NCT04939610 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors(LuMIERE) | recruiting | Phase 1 / Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 6 | Jul 24, 2026 | clinicaltrials |
| NCT06445517 | Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma | recruiting | Phase 1 | 60 | InSilico Medicine Hong Kong LimitedINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07002203 | Personalized Neoantigen Peptide Vaccines for Solid Tumors | recruiting | Phase 1 / Phase 2 | 10 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 10, 2026source: clinicaltrials